EurekaMag
+ Translate
+ Most Popular
Spermatogenic and steroidogenic impairment after chromium treatment in rats
Prediction of enthalpy of formation based on refined crystal structures of multisite compounds; Part 1, Theories and examples
Intrastromal photorefractive keratectomy for myopia by Nd:YLF picosecond laser
Teachers' beliefs about the role of prior language knowledge in learning and how these influence teaching practices
Classification and genesis of submarine iron-manganese deposits
Insecta a Cl. G. N. Potanin in China et in Mongolia novissime lecta. XVII. Hemiptera-Heteroptera
On the occurrence of the splendid genus Machaerothrix Haupt in Tsushima, with some remarks on the genus (Hymenoptera, Pompilidae)
Enamel craze lines
Gynecologic examination of the child and the adolescent
Periosteal osteoclasts, skeletal development and ageing
Fibrodysplasia ossificans progressiva in a Nigerian: a case report
The chronically ill patient with anorexia nervosa development, phenomenology, and therapeutic considerations
Kummelonautilus taiwanum sp. nov. (Nautilida) from the early Miocene Shihmen Formation, Chungliao, Nantou, west-central Taiwan
Efficacy of Droncit against Dipylidium caninum in dogs
Pierids of the genus Euchloe Klots (Lepidoptera, Pieridae) from Siberia and the Far East.
C5A anaphylatoxin and its seven transmembrane-segment receptor
Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors?
Empirical comparisons of proportional hazards regression, Poisson regression, and logistic regression in the analysis of occupational cohort data
Pollination of flowers of sweet and sour cherries
Isopodi terrestri raccolti nell' Estremo Oriente
Morphometric observations on Dipylidium caninum from dogs and cats in Austria
Chelation effectiveness of zinc proteinates demonstrated
Alopecia--a psychosomatic disease picture? I. Review of the literature
Monitoring equity in health and healthcare: a conceptual framework
Hemodynamic evaluation of the Biocor heterologous prosthesis

A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis


A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis



American Journal of Tropical Medicine and Hygiene 77(4): 640-646



ISSN/ISBN: 0002-9637

PMID: 17978064

Azithromycin was compared with meglumine antimoniate for treatment of patients with cutaneous leishmaniasis. Patients were randomized to receive oral azithromycin, 500 mg/day (22 patients) or intramuscular meglumine antimoniate, 10 mg Sb/kg/day (23 patients), both for 28 days, with a second cycle of 15 days if necessary, and followed-up for one year after completion of treatment. Efficacy, defined as complete re-epithelization without relapse for 12 months after completing therapy, was 82.6% (95% confidence interval [CI] = 67-98%) for meglumine antimoniate and 45.5% (95% Cl = 25-66%) for azithromycin. All patients who failed treatment with azithromycin were treated with meglumine antimoniate and clinically cured. Azithromycin was well tolerated; meglumine antimoniate caused arthralgias and local symptoms in 78% of the patients. In 17 cases, species identification was obtained; Leishmania (Viannia) braziliensis was identified in all of them. For the treatment of American cutaneous leishmaniasis caused by L. (V) braziliensis, meglumine antimoniate is significatively more efficacious than azithromycin, which was clinically curative in almost half of the patients and well-tolerated.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 014835423

Download citation: RISBibTeXText

Related references

A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. Anais Brasileiros de Dermatologia 86(6): 1092-1101, 2011

Genotypic profiles of Leishmania (Viannia) braziliensis strains from cutaneous leishmaniasis patients and their relationship with the response to meglumine antimoniate treatment: a pilot study. Parasite 24: 34, 2017

In vitro sensitivity of paired Leishmania (Viannia) braziliensis samples isolated before meglumine antimoniate treatment and after treatment failure or reactivation of cutaneous leishmaniasis. Disease Markers 2015: 943236, 2015

Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. American Journal of Tropical Medicine and Hygiene 65(5): 456-465, 2001

Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. American Journal of Tropical Medicine and Hygiene 64(3-4): 187-193, 2001

Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis. Revista Da Sociedade Brasileira de Medicina Tropical 29(5): 447-453, 1996

Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. Aids 13(9): 1063-1069, 1999

Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis. Journal of Antimicrobial ChemoTherapy 70(12): 3283-3290, 2015

Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis. Journal of parasitology 93(3): 688-693, 2007

In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B. Tropical Medicine and International Health: Tm and Ih 15(1): 68-76, 2010

Clinical features of cutaneous and disseminated cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis in Paraty, Rio de Janeiro. International Journal of Dermatology 47(9): 926-932, 2008

Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial. Plos one 8(6): E66123, 2013

Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Tropica 103(1): 33-40, 2007

Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. American Journal of Tropical Medicine and Hygiene 84(2): 255-260, 2011

Cases of american cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis in the towns of Cosmópolis and Indaiatuba-region of Campinas, in São Paulo, Brazil. Revista Da Sociedade Brasileira de Medicina Tropical 29(5): 419-424, 1996